Authum Investment & Infrastructure to Acquire 3% Stake in Serovia Pharma
Authum Investment & Infrastructure plans to invest ₹30 crore for a 3% stake in Serovia Pharma through a Series B funding round. The investment will be made via Compulsory Convertible Preference Shares (CCPS), marking Authum's strategic entry into the pharmaceutical sector.

*this image is generated using AI for illustrative purposes only.
Authum Investment & Infrastructure is set to make a strategic move in the pharmaceutical sector with a planned investment in Serovia Pharma. The company has announced its intention to acquire a 3% stake in Serovia Pharma through a Series B funding round.
Investment Details
Item | Detail |
---|---|
Stake Acquisition | 3% |
Investment Vehicle | Series B Compulsory Convertible Preference Shares (CCPS) |
Investment Amount | ₹30.00 crore |
Strategic Implications
This transaction marks a significant step for Authum Investment & Infrastructure as it expands its portfolio into the pharmaceutical industry. By investing in Serovia Pharma, Authum is positioning itself to potentially benefit from growth opportunities in the healthcare sector.
About the Investment
The investment will be made through Compulsory Convertible Preference Shares (CCPS), which are a type of convertible security that must be converted into common stock at a predetermined date or event. This structure allows Authum to have a stake in Serovia Pharma with the potential for future equity conversion.
Market Impact
The 3% stake represents a strategic investment for Authum Investment & Infrastructure. This move could signal the company's interest in diversifying its investment portfolio and tapping into the growth potential of the pharmaceutical industry.
Investors and market analysts will likely be watching closely to see how this investment performs and whether it leads to further involvement in the healthcare sector for Authum Investment & Infrastructure.